104 related articles for article (PubMed ID: 10429507)
1. Clinical imaging of multidrug resistance in cancer.
Del Vecchio S; Ciarmiello A; Salvatore M
Q J Nucl Med; 1999 Jun; 43(2):125-31. PubMed ID: 10429507
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
[TBL] [Abstract][Full Text] [Related]
3. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
5. Scintigraphic detection of multidrug resistance in cancer.
Del Vecchio S; Ciarmiello A; Salvatore M
Cancer Biother Radiopharm; 2000 Aug; 15(4):327-37. PubMed ID: 11041017
[TBL] [Abstract][Full Text] [Related]
6. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
[TBL] [Abstract][Full Text] [Related]
7. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
[TBL] [Abstract][Full Text] [Related]
10. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
11. Tetrofosmin as predictors of tumour response.
Fuster D; Viñolas N; Mallafré C; Pavia J; Martín F; Pons F
Q J Nucl Med; 2003 Mar; 47(1):58-62. PubMed ID: 12714956
[TBL] [Abstract][Full Text] [Related]
12. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
13. Non-small cell lung cancer functional imaging: increased hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cytotoxic treatment.
Koukourakis MI; Koukouraki S; Giatromanolaki A; Skarlatos J; Georgoulias V; Karkavitsas N
Clin Cancer Res; 1997 May; 3(5):749-54. PubMed ID: 9815745
[TBL] [Abstract][Full Text] [Related]
14. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
[TBL] [Abstract][Full Text] [Related]
15. Cationic lipophilic radiotracers for functional imaging of multidrug resistance.
Gomes CM
Curr Radiopharm; 2012 Apr; 5(2):113-23. PubMed ID: 22280111
[TBL] [Abstract][Full Text] [Related]
16. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet?
Kostakoglu L
Clin Lymphoma; 2002 Mar; 2(4):242-8. PubMed ID: 11970764
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates.
Bae KT; Piwnica-Worms D
Q J Nucl Med; 1997 Jun; 41(2):101-10. PubMed ID: 9203849
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
